Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trialRupert Bartsch, Matthias Preusser, Zsuzsanna Bagó-Horváth et al.|Nature Medicine|2022Cited by 395
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastasesRupert Bartsch, Matthias Preusser, Anna S. Berghoff et al.|Neuro-Oncology|2024Cited by 60
280P Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trialRupert Bartsch, Matthias Preusser, Anna S. Berghoff et al.|Annals of Oncology|2021Cited by 23
165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trialRupert Bartsch, Matthias Preusser, Anna S. Berghoff et al.|Annals of Oncology|2022Cited by 17
Abstract PO2-04-05: FINAL OUTCOME ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-POSITIVE BREAST CANCER PATIENTS WITH ACTIVE BRAIN METASTASESRupert Bartsch, Matthias Preusser, Anna S. Berghoff et al.|Cancer Research|2024Cited by 2